Model for End-Stage Liver Disease Score Predicts the Mortality of Patients with Coronary Heart Disease Who Underwent Percutaneous Coronary Intervention
Table 1
Characteristics of participants of the two groups.
Variables
MELD integral quartile
MELD 1.0 n (%)
MELD 2.0 n (%)
MELD 3.0 n (%)
MELD 4.0 n (%)
Total n (%) or mean
Chi-square or F
value
Age, years
59.25 ± 10.23
58.41 ± 10.75
59.61 ± 10.88
60.79 ± 11.20
59.51 ± 10.80
11.311
<0.001
Female n (%)
621 (46.3%)
341 (25.4%)
249 (18.5%)
177 (13.2%)
1388 (25.8%)
442.798
<0.001
Smoking, n (%)
413 (30.8%)
517 (38.6%)
594 (44.0%)
625 (46.6%)
2149 (40.0%)
82.289
<0.001
Alcohol drinking, n (%)
313 (23.3%)
380 (28.3%)
433 (32.1%)
440 (32.8%)
1566 (29.1%)
36.872
<0.001
Diabetes, n (%)
368 (27.4%)
320 (23.9%)
294 (21.8%)
330 (24.6%)
1312 (24.4%)
11.844
0.008
Hypertension, n (%)
595 (44.3%)
545 (40.6%)
584 (43.3%)
588 (43.8%)
2312 (43.0%)
4.46
0.226
SBP, mmHg
128.16 ± 18.34
127.05 ± 18.86
126.88 ± 18.60
126.33 ± 19.25
127.11 ± 18.77
2.241
0.081
DBP, mmHg
76.56 ± 11.07
76.33 ± 11.10
76.46 ± 11.42
75.70 ± 11.54
76.26 ± 11.29
1.571
0.194
BUN, mmol/L
5.01 ± 1.47
5.39 ± 1.48
5.60 ± 1.56
6.11 ± 1.91
5.53 ± 1.66
108.233
<0.001
GLU, mmol/L
6.72 ± 3.41
6.55 ± 2.89
6.41 ± 3.12
6.59 ± 3.08
6.57 ± 3.13
2.248
0.081
TG, mmol/L
1.99 ± 1.37
1.92 ± 1.37
1.87 ± 1.18
1.84 ± 1.19
1.90 ± 1.28
3.636
0.012
TC, mmol/L
3.99 ± 1.08
3.95 ± 1.07
3.97 ± 1.15
3.94 ± 1.13
3.96 ± 1.11
0.553
0.646
LDL-C, mmol/L
2.46 ± 0.88
2.47 ± 0.90
2.47 ± 0.97
2.48 ± 0.91
2.46 ± 0.92
0.176
0.913
HDL-C, mmol/L
1.01 ± 0.44
1.02 ± 0.52
1.04 ± 0.50
1.01 ± 0.46
1.02 ± 0.48
0.817
0.484
ApoA1, mmol/L
1.16 ± 0.31
1.17 ± 0.33
1.17 ± 0.32
1.16 ± 0.31
1.17 ± 0.32
0.509
0.676
ApoB, mmol/L
0.85 ± 0.33
0.86 ± 0.42
0.86 ± 0.44
0.84 ± 0.37
0.85 ± 0.39
0.786
0.502
Lp (a), mmol/L
227.95 ± 184.33
227.11 ± 188.82
215.03 ± 164.59
212.86 ± 164.59
220.75 ± 177.76
2.586
0.051
EF (%)
61.37 ± 7.03
60.96 ± 6.95
61.15 ± 6.94
60.96 ± 7.14
61.11 ± 7.02
0.919
0.431
LVEDD, mm
49.81 ± 5.44
49.99 ± 5.49
49.84 ± 5.58
50.17 ± 5.63
49.95 ± 5.53
1.038
0.375
CCB, n (%)
157 (11.8%)
166 (12.4%)
160 (11.9%)
138 (10.4%)
621 (11.6%)
3.049
0.384
β-Blocker, n (%)
515 (38.6%)
557 (41.7%)
523 (38.9%)
567 (42.5%)
2162 (40.4%)
6.345
0.092
ACEI or ARB,n (%)
301 (22.6%)
312 (23.4%)
292 (21.7%)
305 (22.9%)
1210 (22.7%)
1.14
0.767
Cr, umol/L
58.49 ± 10.68
70.57 ± 10.26
78.65 ± 11.80
94.97 ± 21.77
75.67 ± 19.58
1511.004
<0.001
Statins, n (%)
690 (52.0%)
743 (55.9%)
733 (54.7%)
727 (54.7%)
2893 (54.3%)
4.44
0.218
New-generation stent, n (%)
1260 (93.9%)
1260 (94.0%)
1275 (94.6%)
1266 (94.4%)
5061 (94.2%)
0.849
0.838
CTO, n (%)
281 (20.9%)
299 (22.3%)
306 (22.7)
364 (27.1%)
1250 (23.3%)
16.312
0.001
ML, n (%)
851 (63.4%)
874 (65.2%)
860 (63.8%)
913 (68.1%)
3498 (65.1%)
7.945
0.047
ACEI, angiotensin-converting enzyme inhibitor; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CCB, calcium channel blocker; Cr, creatinine; CTO, chronic total occlusion lesions; DBP, diastolic blood pressure; EF, ejection fraction; GLU, glucose; HDL-C, high-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic dimension; LDL-C, low-density lipoprotein cholesterol; Lp (a), lipoprotein a; MELD, model for end-stage liver disease; ML, multivessel lesions; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; UA, uric acid. Note. The boldfaced values indicate p < 0.05.
